Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.

ABSTRACT:

Background

When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (""contact days'') can help contextualize expected time use with each treatment. We assessed contact days in a completed randomized clinical trial.

Patients and methods

We conducted a secondary analysis of the CCTG LY.12 RCT that evaluated 2-3 cycles of gemcitabine, dexamethasone, and cisplatin (GDP) vs. dexamethasone, cytarabine, and cisplatin (DHAP) in 619 patients with relapsed/refractory lymphoma prior to stem cell transplant. Primary analyses reported similar response rates and survival. We calculated patient-level "contact days" by analyzing trial forms. The study period was from assignment to progression or transplant. Days without healthcare contact

SUBMITTER: Gupta A 

PROVIDER: S-EPMC10485297 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature